PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2006 by Therion Biologics Corporation.
Recruitment status was  Active, not recruiting
Information provided by:
Therion Biologics Corporation Identifier:
First received: July 30, 2004
Last updated: February 7, 2006
Last verified: February 2006

July 30, 2004
February 7, 2006
June 2004
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00088660 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen
A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen
The objectives of this multi-center, randomized, controlled trial are to evaluate the safety and efficacy of PANVAC-VF in combination with Granulocyte-macrophage colony-stimulating factor (GM-CSF) versus best supportive care or palliative chemotherapy.

PANVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the body can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells. These targets are called Tumor Associated Antigens, or TAA's. This trial will help determine if this vaccine can help fight cancer.

All patients will be required to sign an informed consent prior to the performance of any study-related procedures. Patients will be screened for eligibility within 14 days prior to their anticipated treatment start date (Day 0). Patients who meet all inclusion and exclusion criteria will be centrally randomized into the study and will receive a unique patient identification number and a treatment assignment. The ratio of active treatment to control is 1:1 (PANVAC-VF: best supportive care or palliative chemotherapy).

Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Pancreatic Cancer
Biological: PANVAC™-VF
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
Not Provided

Inclusion Criteria:

  • Patients > 18 years of age who have been vaccinated against smallpox;
  • Histologically confirmed diagnosis of adenocarcinoma of the pancreas;
  • Patient has metastatic (Stage IV) disease;
  • ECOG performance status 0-1;
  • Failed a gemcitabine-containing chemotherapeutic regimen within 3 months of study entry.

Exclusion Criteria:

  • Prior or concurrent immunotherapy for cancer;
  • Radiation therapy within 28 days prior to registration;
  • Systemic corticosteroid therapy (except inhaled or topical steroids) within 28 days of registration;
  • Significant cardiovascular abnormalities or diseases;
  • Known positive for HIV, hepatitis B and/or C;
  • Evidence of immunodeficiency or immune suppression.
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Therion Biologics Corporation
Not Provided
Not Provided
Therion Biologics Corporation
February 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP